EUVIMEDOpdag EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review

Richard B Lipton iD, Astrid Gendolla, Lucy Abraham iD, Aaron Jenkins iD, Jersen Telfort, Karin Hygge Blakeman iD, Phillip A Saccone, Iwona Pustulka iD, Iain Fotheringham iD, Anita Engh iD

Headache: The Journal of Head and Face Pain · 2025-01 · 65 (1) · 164-179

DOI: 10.1111/head.14854 ↗

At a glance

Systematische Übersicht in Headache: The Journal of Head and Face Pain, published online on 2024-11-27. Written by Richard B Lipton and 9 co-authors. Institution: Albert Einstein College of Medicine, Bronx, New York, USA. Major MEDLINE topics: Migraine Disorders, Tryptamines, Cost of Illness. Cited 11 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Pfizer.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This review was conducted to systematically identify evidence characterizing patients with migraine who are unsuitable for triptans.

Background

Triptans are not suitable as first‐line treatment for all patients with migraine due to contraindications, lack of efficacy, and/or poor tolerability. However, there is debate about the frequency and characteristics of these patients and the burden they experience.

Methods

MEDLINE, Embase, and conference abstracts (2011–2022) were reviewed for evidence on patients with migraine unsuitable for triptans for any reason. Data from publications describing the frequency and characteristics of this group, as well as the clinical, humanistic, or economic burden of disease in this population, were extracted.

Results

Of 1460 records screened, 29 publications met inclusion criteria. Persistence with triptans was low; 51%–66% of patients starting a new triptan did not refill it, and 43%–100% discontinued their initial triptan over 2 years. In one study, 14% of patients with migraine reported prior discontinuation/failure of ≥ 2 triptans due to inadequate efficacy or poor tolerability. Up to 15% of patients with migraine had triptan contraindications, and ≥ 20% of patients receiving triptans had contraindications. In four studies, 10%–44% of patients who tried triptans had insufficient response, although definitions varied. Patients who achieved a sufficient response typically did so with their first triptan; few became responders with additional triptans. Of patients who did not respond to one to two triptans and received another, 45% were dissatisfied with the final triptan. Approximately half of patients who tried two to three triptans had an insufficient response. Greater disability, impact of disease, and depression were reported in triptan discontinuers compared to those with sustained use. Worse quality of life scores and utility values were reported in triptan insufficient versus sufficient responders, as were greater migraine‐related costs, work impairment, and health‐care resource utilization.

Conclusion

The total population of patients unsuitable for triptans is uncertain, but the literature highlights a large group who cannot or do not persist with triptans, and current evidence suggests a high burden in this population and an unmet need for new therapeutic options. Further research is needed to determine the frequency of unsuitability for triptans more precisely and to assess the associated burden.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersTryptaminesCost of IllnessHumans

Author keywords

insufficent responsemigrainetreatmenttriptan

Substances

Tryptamines

Authors and institutions

  • Albert Einstein College of Medicine, Bronx, New York, USA.
  • Montefiore Medical Center, Bronx, New York, USA.
  • Private Practice, Essen, Germany.
  • Pfizer R&D UK Ltd., Surrey, UK.
  • Pfizer Inc., New York, New York, USA.
  • Pfizer AB, Stockholm, Sweden.

ORCID profiles: Richard B Lipton, Lucy Abraham, Aaron Jenkins, Karin Hygge Blakeman, Iwona Pustulka, Iain Fotheringham, Anita Engh

Funding

  • Pfizer

Cite

APA

Lipton, R. B., Gendolla, A., Abraham, L., Jenkins, A., Telfort, J., Blakeman, K. H., Saccone, P. A., Pustulka, I., Fotheringham, I., & Engh, A. (2025). Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review. Headache: The Journal of Head and Face Pain, 65(1), 164-179. https://doi.org/10.1111/head.14854

Vancouver

Lipton RB, Gendolla A, Abraham L, Jenkins A, Telfort J, Blakeman KH, et al. Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review. Headache: The Journal of Head and Face Pain. 2025;65(1):164-179. doi:10.1111/head.14854

BibTeX
@article{Lipton2025,
  author = {Lipton, Richard B and Gendolla, Astrid and Abraham, Lucy and Jenkins, Aaron and Telfort, Jersen and Blakeman, Karin Hygge and Saccone, Phillip A and Pustulka, Iwona and Fotheringham, Iain and Engh, Anita},
  title = {Relative frequency, characteristics, and disease burden of patients with migraine unsuitable for triptan treatment: A systematic literature review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2025},
  volume = {65},
  number = {1},
  pages = {164--179},
  doi = {10.1111/head.14854}
}
Start for free →